Product Name

  • Name

    Prulifloxacin

  • EINECS 819-932-1
  • CAS No. 123447-62-1
  • Article Data9
  • CAS DataBase
  • Density 1.62 g/cm3
  • Solubility Slightly soluble in dimethyl formamide, 0.1M NaOH or glacial acetic acid; insoluble in water or methanol
  • Melting Point 211-214°C
  • Formula C21H20FN3O6S
  • Boiling Point 633.2 °C at 760 mmHg
  • Molecular Weight 461.471
  • Flash Point 336.8 °C
  • Transport Information
  • Appearance Yellow or slightly yellow power
  • Safety
  • Risk Codes
  • Molecular Structure Molecular Structure of 123447-62-1 (Prulifloxacin)
  • Hazard Symbols
  • Synonyms 1H,4H-[1,3]Thiazeto[3,2-a]quinoline-3-carboxylic acid,6-fluoro-1-methyl-7-[4-[(5-methyl- 2-oxo-1,3-dioxol-4-yl)methyl]-1- piperazinyl]-4-oxo-;PUFX;(+-)-7-(4-((Z)-2,3-Dihydroxy-2-butenyl)-1-piperazinyl)-6-fluoro-1-methyl-4-oxo-1H,4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid, cyclic carbonate;Sword;Sword (TN);
  • PSA 134.43000
  • LogP 2.64270

Synthetic route

4-bromomethyl-1,3-dioxa-5-methylcyclopentene-2-one
80715-22-6

4-bromomethyl-1,3-dioxa-5-methylcyclopentene-2-one

ulifloxacin
112984-60-8

ulifloxacin

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
With potassium hydrogencarbonate In N,N-dimethyl-formamide at 0℃; for 5h; Large scale;95.4%
With potassium hydrogencarbonate In N,N-dimethyl-formamide for 5h; Ambient temperature;62%
Stage #1: ulifloxacin With potassium hydrogencarbonate In acetonitrile at 25 - 30℃;
Stage #2: 4-bromomethyl-1,3-dioxa-5-methylcyclopentene-2-one at 15 - 30℃; for 27 - 28.25h;
Stage #1: 4-bromomethyl-1,3-dioxa-5-methylcyclopentene-2-one; ulifloxacin With potassium hydrogencarbonate In N,N-dimethyl-formamide at 0 - 28℃; for 3 - 4h;
Stage #2: With hydrogenchloride In chloroform; water for 0.25h; pH=0.8 - 1.0;
Stage #1: ulifloxacin With N-ethyl-N,N-diisopropylamine In acetonitrile at 20℃; for 0.166667h;
Stage #2: 4-bromomethyl-1,3-dioxa-5-methylcyclopentene-2-one In acetonitrile at 10 - 30℃; for 21h; Product distribution / selectivity;
4-bromomethyl-1,3-dioxa-5-methylcyclopentene-2-one
80715-22-6

4-bromomethyl-1,3-dioxa-5-methylcyclopentene-2-one

ulifloxacin
112984-60-8

ulifloxacin

A

prulifloxacin
123447-62-1

prulifloxacin

B

6-fluoro-1-methyl-4-oxo-7-<4-<(2-oxo-1-methylenepropyl)oxycarbonyl>-1-piperazinyl>-4H-<1,3>thiazeto<3,2-a>quinoline-3-carboxylic acid
156834-57-0

6-fluoro-1-methyl-4-oxo-7-<4-<(2-oxo-1-methylenepropyl)oxycarbonyl>-1-piperazinyl>-4H-<1,3>thiazeto<3,2-a>quinoline-3-carboxylic acid

C

7-<4-<1-<4-(3-carboxy-6-fluoro-1-methyl-4-oxo-4H-<1,3>thiazeto<3,2-a>quinolin-7-yl)>-1-piperazinylmethyl>-2-oxopropoxycarbonyl>-1-piperazinyl>-6-fluoro-1-methyl-4-oxo-4H-<1,3>thazeto<3,2-a>quinoline-3-carboxylic acid

7-<4-<1-<4-(3-carboxy-6-fluoro-1-methyl-4-oxo-4H-<1,3>thiazeto<3,2-a>quinolin-7-yl)>-1-piperazinylmethyl>-2-oxopropoxycarbonyl>-1-piperazinyl>-6-fluoro-1-methyl-4-oxo-4H-<1,3>thazeto<3,2-a>quinoline-3-carboxylic acid

D

1,1-bis<(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl>-4-(3-carboxy-6-fluoro-1-methyl-4-oxo-4H-<1,3>thiazeto<3,2-a>quinoline-7-yl)-1-piperazinium bromide

1,1-bis<(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl>-4-(3-carboxy-6-fluoro-1-methyl-4-oxo-4H-<1,3>thiazeto<3,2-a>quinoline-7-yl)-1-piperazinium bromide

Conditions
ConditionsYield
With potassium hydrogencarbonate In N,N-dimethyl-formamide at 30℃; for 2h; Product distribution; Rate constant; various periods of time (3 h); activation energy 29.1 kJ mol-1;A 93.6 % Spectr.
B 2.0 % Spectr.
C 0.5 % Spectr.
D 1.1 % Spectr.
...Expand
4-bromomethyl-1,3-dioxa-5-methylcyclopentene-2-one
80715-22-6

4-bromomethyl-1,3-dioxa-5-methylcyclopentene-2-one

ulifloxacin
112984-60-8

ulifloxacin

A

prulifloxacin
123447-62-1

prulifloxacin

B

6-Fluoro-1-methyl-7-[4-(5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl)-piperazin-1-yl]-4-oxo-4H-2-thia-8b-aza-cyclobuta[a]naphthalene-3-carboxylic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester

6-Fluoro-1-methyl-7-[4-(5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl)-piperazin-1-yl]-4-oxo-4H-2-thia-8b-aza-cyclobuta[a]naphthalene-3-carboxylic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester

Conditions
ConditionsYield
With potassium hydrogencarbonate for 3h; Product distribution; also in presence of DIPEA, car. concn. of substrates;
...Expand
4-chloromethyl-5-methyl-1,3-dioxol-2-one
80841-78-7

4-chloromethyl-5-methyl-1,3-dioxol-2-one

ulifloxacin
112984-60-8

ulifloxacin

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; sodium bromide 1.) DMF, 303 K, 2 h, 2.) DMF, 304 K, 1 h; Yield given. Multistep reaction;
3,4-difluorophenyl isothiocyanate
113028-75-4

3,4-difluorophenyl isothiocyanate

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 1.) KOH / 1.) dioxane, RT, 30 min., 2.) 4 deg C, 15 h
2: 2.22 g / K2CO3 / dimethylformamide / 1 h / 70 °C
3: 0.350 g / PPE / 1.5 h / 80 °C
4: 84 percent / dimethylformamide / Ambient temperature
5: 88 percent / KOH / 2-methyl-propan-2-ol; H2O / 1 h / 50 - 60 °C
6: 62 percent / KHCO3 / dimethylformamide / 5 h / Ambient temperature
View Scheme
Multi-step reaction with 8 steps
1: 1.) KOH / 1.) dioxane, RT, 30 min., 2.) 4 deg C, 15 h
2: dimethylformamide / 1.) 0 deg C, 1.5 h, 2.) RT, 2 h
3: 58 percent / diphenyl ether / 5 h / 240 °C
4: 99 percent / 35percent HCl / ethanol / 2 h / Ambient temperature
5: 47 percent / K2CO3, KI / dimethylformamide / 0.5 h / 105 - 110 °C
6: 84 percent / dimethylformamide / Ambient temperature
7: 88 percent / KOH / 2-methyl-propan-2-ol; H2O / 1 h / 50 - 60 °C
8: 62 percent / KHCO3 / dimethylformamide / 5 h / Ambient temperature
View Scheme
ethyl 7,6-difluoro-4-hydroxy-2-mercaptoquinoline-3-carboxylate
84339-06-0

ethyl 7,6-difluoro-4-hydroxy-2-mercaptoquinoline-3-carboxylate

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 47 percent / K2CO3, KI / dimethylformamide / 0.5 h / 105 - 110 °C
2: 84 percent / dimethylformamide / Ambient temperature
3: 88 percent / KOH / 2-methyl-propan-2-ol; H2O / 1 h / 50 - 60 °C
4: 62 percent / KHCO3 / dimethylformamide / 5 h / Ambient temperature
View Scheme
3,4-difluorophenyl dithiocarbamic acid triethylammonium
144514-15-8

3,4-difluorophenyl dithiocarbamic acid triethylammonium

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: ethyl chloroformate, triethylamine / CHCl3 / 3.5 h / Ambient temperature
2: 1.) KOH / 1.) dioxane, RT, 30 min., 2.) 4 deg C, 15 h
3: 2.22 g / K2CO3 / dimethylformamide / 1 h / 70 °C
4: 0.350 g / PPE / 1.5 h / 80 °C
5: 84 percent / dimethylformamide / Ambient temperature
6: 88 percent / KOH / 2-methyl-propan-2-ol; H2O / 1 h / 50 - 60 °C
7: 62 percent / KHCO3 / dimethylformamide / 5 h / Ambient temperature
View Scheme
Multi-step reaction with 9 steps
1: ethyl chloroformate, triethylamine / CHCl3 / 3.5 h / Ambient temperature
2: 1.) KOH / 1.) dioxane, RT, 30 min., 2.) 4 deg C, 15 h
3: dimethylformamide / 1.) 0 deg C, 1.5 h, 2.) RT, 2 h
4: 58 percent / diphenyl ether / 5 h / 240 °C
5: 99 percent / 35percent HCl / ethanol / 2 h / Ambient temperature
6: 47 percent / K2CO3, KI / dimethylformamide / 0.5 h / 105 - 110 °C
7: 84 percent / dimethylformamide / Ambient temperature
8: 88 percent / KOH / 2-methyl-propan-2-ol; H2O / 1 h / 50 - 60 °C
9: 62 percent / KHCO3 / dimethylformamide / 5 h / Ambient temperature
View Scheme
ethyl 6,7-difluoro-1-methyl-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylate
113046-72-3

ethyl 6,7-difluoro-1-methyl-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylate

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 84 percent / dimethylformamide / Ambient temperature
2: 88 percent / KOH / 2-methyl-propan-2-ol; H2O / 1 h / 50 - 60 °C
3: 62 percent / KHCO3 / dimethylformamide / 5 h / Ambient temperature
View Scheme
ethyl 6,7-difluoro-4-hydroxy-2-<(methoxymethyl)thio>-quinoline-3-carboxylate
113028-77-6

ethyl 6,7-difluoro-4-hydroxy-2-<(methoxymethyl)thio>-quinoline-3-carboxylate

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 99 percent / 35percent HCl / ethanol / 2 h / Ambient temperature
2: 47 percent / K2CO3, KI / dimethylformamide / 0.5 h / 105 - 110 °C
3: 84 percent / dimethylformamide / Ambient temperature
4: 88 percent / KOH / 2-methyl-propan-2-ol; H2O / 1 h / 50 - 60 °C
5: 62 percent / KHCO3 / dimethylformamide / 5 h / Ambient temperature
View Scheme
3-(3,4-difluorophenyl)-4-methyl<1,3>thiazetidin-2-ylidenemalonate
144514-35-2

3-(3,4-difluorophenyl)-4-methyl<1,3>thiazetidin-2-ylidenemalonate

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 0.350 g / PPE / 1.5 h / 80 °C
2: 84 percent / dimethylformamide / Ambient temperature
3: 88 percent / KOH / 2-methyl-propan-2-ol; H2O / 1 h / 50 - 60 °C
4: 62 percent / KHCO3 / dimethylformamide / 5 h / Ambient temperature
View Scheme
diethyl<<(3,4-difluorophenyl)amino><(methoxymethyl)-thio>methylene>malonate
113028-76-5

diethyl<<(3,4-difluorophenyl)amino><(methoxymethyl)-thio>methylene>malonate

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 58 percent / diphenyl ether / 5 h / 240 °C
2: 99 percent / 35percent HCl / ethanol / 2 h / Ambient temperature
3: 47 percent / K2CO3, KI / dimethylformamide / 0.5 h / 105 - 110 °C
4: 84 percent / dimethylformamide / Ambient temperature
5: 88 percent / KOH / 2-methyl-propan-2-ol; H2O / 1 h / 50 - 60 °C
6: 62 percent / KHCO3 / dimethylformamide / 5 h / Ambient temperature
View Scheme
ethyl 6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylate
113028-17-4

ethyl 6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylate

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 88 percent / KOH / 2-methyl-propan-2-ol; H2O / 1 h / 50 - 60 °C
2: 62 percent / KHCO3 / dimethylformamide / 5 h / Ambient temperature
View Scheme
Multi-step reaction with 2 steps
1.1: potassium hydroxide; water / 1 h / 80 - 85 °C
1.2: 1 h / 20 °C / pH 6.5 - 7
2.1: N-ethyl-N,N-diisopropylamine / acetonitrile / 0.17 h / 20 °C
2.2: 21 h / 10 - 30 °C
View Scheme
[[(3,4-difluorophenyl)amino]-mercaptomethylene]-malonic acid diethyl ester potassium salt

[[(3,4-difluorophenyl)amino]-mercaptomethylene]-malonic acid diethyl ester potassium salt

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 2.22 g / K2CO3 / dimethylformamide / 1 h / 70 °C
2: 0.350 g / PPE / 1.5 h / 80 °C
3: 84 percent / dimethylformamide / Ambient temperature
4: 88 percent / KOH / 2-methyl-propan-2-ol; H2O / 1 h / 50 - 60 °C
5: 62 percent / KHCO3 / dimethylformamide / 5 h / Ambient temperature
View Scheme
Multi-step reaction with 7 steps
1: dimethylformamide / 1.) 0 deg C, 1.5 h, 2.) RT, 2 h
2: 58 percent / diphenyl ether / 5 h / 240 °C
3: 99 percent / 35percent HCl / ethanol / 2 h / Ambient temperature
4: 47 percent / K2CO3, KI / dimethylformamide / 0.5 h / 105 - 110 °C
5: 84 percent / dimethylformamide / Ambient temperature
6: 88 percent / KOH / 2-methyl-propan-2-ol; H2O / 1 h / 50 - 60 °C
7: 62 percent / KHCO3 / dimethylformamide / 5 h / Ambient temperature
View Scheme
3,4-difluoroaniline
3863-11-4

3,4-difluoroaniline

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1: 0 °C
2: ethyl chloroformate, triethylamine / CHCl3 / 3.5 h / Ambient temperature
3: 1.) KOH / 1.) dioxane, RT, 30 min., 2.) 4 deg C, 15 h
4: 2.22 g / K2CO3 / dimethylformamide / 1 h / 70 °C
5: 0.350 g / PPE / 1.5 h / 80 °C
6: 84 percent / dimethylformamide / Ambient temperature
7: 88 percent / KOH / 2-methyl-propan-2-ol; H2O / 1 h / 50 - 60 °C
8: 62 percent / KHCO3 / dimethylformamide / 5 h / Ambient temperature
View Scheme
Multi-step reaction with 10 steps
1: 0 °C
2: ethyl chloroformate, triethylamine / CHCl3 / 3.5 h / Ambient temperature
3: 1.) KOH / 1.) dioxane, RT, 30 min., 2.) 4 deg C, 15 h
4: dimethylformamide / 1.) 0 deg C, 1.5 h, 2.) RT, 2 h
5: 58 percent / diphenyl ether / 5 h / 240 °C
6: 99 percent / 35percent HCl / ethanol / 2 h / Ambient temperature
7: 47 percent / K2CO3, KI / dimethylformamide / 0.5 h / 105 - 110 °C
8: 84 percent / dimethylformamide / Ambient temperature
9: 88 percent / KOH / 2-methyl-propan-2-ol; H2O / 1 h / 50 - 60 °C
10: 62 percent / KHCO3 / dimethylformamide / 5 h / Ambient temperature
View Scheme
6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl-1-piperazinyl]-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid acetonitrile solvate
791105-27-6

6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl-1-piperazinyl]-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid acetonitrile solvate

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
at 50 - 80℃; under 20 Torr; for 24h; Product distribution / selectivity; Neat (no solvent);
In acetonitrile at 80℃; Purification / work up;
6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl-1-piperazinyl]-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid hydrochloride

6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl-1-piperazinyl]-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid hydrochloride

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
With triethylamine In methanol; dichloromethane at 0 - 5℃; for 1.5h; Product distribution / selectivity;
ethyl 5,6-difluoro-1-methyl-4-oxo-4H-<1,3>thiazeto<3,2-a>quinoline carboxylate

ethyl 5,6-difluoro-1-methyl-4-oxo-4H-<1,3>thiazeto<3,2-a>quinoline carboxylate

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: N,N-dimethyl-formamide / 9.17 h / 10 - 55 °C
2.1: potassium hydroxide; water / 1 h / 80 - 85 °C
2.2: 1 h / 20 °C / pH 6.5 - 7
3.1: N-ethyl-N,N-diisopropylamine / acetonitrile / 0.17 h / 20 °C
3.2: 21 h / 10 - 30 °C
View Scheme
4,5-Dimethyl-1,3-dioxole-2-one
37830-90-3

4,5-Dimethyl-1,3-dioxole-2-one

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N-Bromosuccinimide / chloroform / Reflux; Large scale
2: potassium hydrogencarbonate / N,N-dimethyl-formamide / 5 h / 0 °C / Large scale
View Scheme
prulifloxacin
123447-62-1

prulifloxacin

6-fluoro-1-methyl-7-<4-<(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl>-1-piperazinyl>-4-oxo-4H-<1,3>thiazeto<3,2-a>quinoline-3-carboxylic acid hydrochloride

6-fluoro-1-methyl-7-<4-<(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl>-1-piperazinyl>-4-oxo-4H-<1,3>thiazeto<3,2-a>quinoline-3-carboxylic acid hydrochloride

Conditions
ConditionsYield
With hydrogenchloride for 6h; Ambient temperature;82%
4-bromomethyl-1,3-dioxa-5-methylcyclopentene-2-one
80715-22-6

4-bromomethyl-1,3-dioxa-5-methylcyclopentene-2-one

prulifloxacin
123447-62-1

prulifloxacin

6-Fluoro-1-methyl-7-[4-(5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl)-piperazin-1-yl]-4-oxo-4H-2-thia-8b-aza-cyclobuta[a]naphthalene-3-carboxylic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester

6-Fluoro-1-methyl-7-[4-(5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl)-piperazin-1-yl]-4-oxo-4H-2-thia-8b-aza-cyclobuta[a]naphthalene-3-carboxylic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide at 39.9℃; for 3h;72%
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 24.9℃; Rate constant; also in presence of DIPA and TNBA, var concn. of DMDO-Br and amines;
prulifloxacin
123447-62-1

prulifloxacin

ornidazole
16773-42-5

ornidazole

6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl)piperazin-1-yl]-4-oxo-4H-2-thia-8b-aza-cycobuta[a]naphthalene-3-carboxylic acid 1-chloromethyl-2-(2-methyl-5-nitro-imidazol-1-yl)ethyl ester

6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl)piperazin-1-yl]-4-oxo-4H-2-thia-8b-aza-cycobuta[a]naphthalene-3-carboxylic acid 1-chloromethyl-2-(2-methyl-5-nitro-imidazol-1-yl)ethyl ester

Conditions
ConditionsYield
With dmap; benzotriazol-1-ol; dicyclohexyl-carbodiimide In N,N-dimethyl-formamide at 20℃; for 16h;65%
C21H27N3O8S2

C21H27N3O8S2

prulifloxacin
123447-62-1

prulifloxacin

Conditions
ConditionsYield
Stage #1: prulifloxacin With benzotriazol-1-ol; dicyclohexyl-carbodiimide In dichloromethane; N,N-dimethyl-formamide at 20℃; for 3h;
Stage #2: C21H27N3O8S2 With dmap In dichloromethane; N,N-dimethyl-formamide at 20℃; for 16h;		60%
4-bromomethyl-1,3-dioxa-5-methylcyclopentene-2-one
80715-22-6

4-bromomethyl-1,3-dioxa-5-methylcyclopentene-2-one

prulifloxacin
123447-62-1

prulifloxacin

1,1-bis<(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl>-4-(3-carboxy-6-fluoro-1-methyl-4-oxo-4H-<1,3>thiazeto<3,2-a>quinoline-7-yl)-1-piperazinium bromide

1,1-bis<(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl>-4-(3-carboxy-6-fluoro-1-methyl-4-oxo-4H-<1,3>thiazeto<3,2-a>quinoline-7-yl)-1-piperazinium bromide

Conditions
ConditionsYield
In N,N-dimethyl-formamide for 34h; Ambient temperature;27%
In N,N-dimethyl-formamide at 30.9℃; Rate constant;
ulifloxacin
112984-60-8

ulifloxacin

prulifloxacin
123447-62-1

prulifloxacin

7-<4-<1-<4-(3-carboxy-6-fluoro-1-methyl-4-oxo-4H-<1,3>thiazeto<3,2-a>quinolin-7-yl)>-1-piperazinylmethyl>-2-oxopropoxycarbonyl>-1-piperazinyl>-6-fluoro-1-methyl-4-oxo-4H-<1,3>thazeto<3,2-a>quinoline-3-carboxylic acid

7-<4-<1-<4-(3-carboxy-6-fluoro-1-methyl-4-oxo-4H-<1,3>thiazeto<3,2-a>quinolin-7-yl)>-1-piperazinylmethyl>-2-oxopropoxycarbonyl>-1-piperazinyl>-6-fluoro-1-methyl-4-oxo-4H-<1,3>thazeto<3,2-a>quinoline-3-carboxylic acid

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 30.9℃; Rate constant;
prulifloxacin
123447-62-1

prulifloxacin

acetonitrile
75-05-8

acetonitrile

6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl-1-piperazinyl]-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid acetonitrile solvate
791105-27-6

6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl-1-piperazinyl]-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid acetonitrile solvate

Conditions
ConditionsYield
at 14.3 - 65℃; Product distribution / selectivity;

Prulifloxacin Chemical Properties

Molecular Structure of Prulifloxacin (CAS NO.123447-62-1):

IUPAC Name: (1R)-6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid 
CAS Registry Number 123447-62-1
Molecular Formula:C21H20FN3O6S
Molecular Weight:461.46
H bond acceptors: 9
H bond donors: 1
Freely Rotating Bonds: 4
Polar Surface Area: 113.92 Å2
Molar Volume: 283.5 cm3
Surface Tension: 82 dyne/cm
Index of Refraction: 1.72
Surface Tension: 82 dyne/cm
Density: 1.62 g/cm3
Flash Point: 336.8 °C
Enthalpy of Vaporization:  98.39 kJ/mol
Boiling Point:  633.2 °C at 760 mmHg
Vapour Pressure:  6.62E-17 mmHg at 25°C
Product Categories: API
Solubility: Slightly soluble in dimethyl formamide, 0.1M NaOH or glacial acetic acid; insoluble in water or methanol
Appearance: Yellow or slightly yellow power
InChI
InChI=1/C21H20FN3O6S/c1-10-16(31-21(29)30-10)9-23-3-5-24(6-4-23)15-8-14-12(7-13(15)22)18(26)17(20(27)28)19-25(14)11(2)32-19/h7-8,11H,3-6,9H2,1-2H3,(H,27,28)
Smiles
o1c(oc(CN2CCN(CC2)c2c(cc3c(c2)n2c(c(c3=O)C(O)=O)S[C@@H]2C)F)c1C)=O

Prulifloxacin Specification

 Prulifloxacin , its cas register number is 123447-62-1. It also can be called (+/-)-7-{4-[(Z)-2,3-Dihydroxy-2-butenyl]-1-piperazinyl}-6-fluoro-1-methyl-4-oxo-1H,4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid cyclic carbonate ; 6-Fluoro-1-methyl-7-(4-(5-methyl-2-oxo-1,3-dioxelen-4-yl)methyl-1-piperazinyl)-4-oxo-4H-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid , it can be used as gatifloxacin for the whole synthetic antibacterial drugs.

Related Products

Hot Products

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View